NEW YORK, Feb. 23 /PRNewswire-FirstCall/ -- Pfizer Inc said today that
a Danish court has granted a preliminary injunction against Nomeco A/S --
the largest pharmaceutical wholesaler in Denmark -- that prohibits the sale
of a generic version of Lipitor by generics manufacturer Ranbaxy. The
injunction, issued by the Bailiff's Court of the Copenhagen City Court in
Denmark and subject to possible appeal by Nomeco, requires Ranbaxy's
generic atorvastatin product to be withdrawn from the Danish market pending
the outcome of a patent infringement trial that has not yet been scheduled.
At issue are three Pfizer patents covering atorvastatin calcium, the
active ingredient in Lipitor, as well as processes and intermediate
compounds used to make atorvastatin. The latest-expiring of the patents
provides coverage for Lipitor through November, 2011. The Bailiff's Court
ruled in Pfizer's favor on all three patents.
"This ruling is another significant milestone in our defense of Lipitor
patents around the world," said Pfizer Senior Vice President and General
Counsel Allen Waxman. "And it's an important outcome for Pfizer and other
medical innovators who invest in high-risk research to develop life-saving
medicines for millions of patients," added Karin Verland, country manager
of Pfizer Denmark.
SOURCE Pfizer Inc
 back to top
Photo Notes:A free corporate logo to accompany this
story is availableimmediately via Wieck Photo Database to any
media with telephoto receiveror electronic darkroom, PC or
Macintosh, that can accept overheadtransmissions. To retrieve a
logo, please call 972-392-0888./ /Company News On-Call:
http://www.prnewswire.com/comp/688250.html
Pfizer's press releases are available through PR Newswire's
Company News On-Call service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html/
CONTACT:
Bryant Haskins, +1-212-733-8719
|
